| Species |
Human |
| Protein Construction |
| mFc (IgG2a) |
BDCA-2 (Phe46-Ile213)
Accession # Q8WTT0-1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized BDCA-2 mFc Chimera, Human at 0.5μg/ml (100μl/well) on the plate can bind AntiBDCA2 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
46.39 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in 20mM Tris, 150mM NaCl, 200mM L-arginine (pH 8.5). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
BDCA-2 is a novel type II C-type lectin specifically expressed by plasmacytoid dendritic cells (PDCs) that can internalize antigen for presentation to T cells. Furthermore, signaling via BDCA-2 may play a role in switching from interferon (IFN)-α/β-controlled to interleukin (IL)-12-controlled immune response pathways, as triggering of BDCA-2 potently inhibits secretion of IFN-α/β by PDCs and thereby promotes IL-12 p70 production in PDCs and other cells. |
| Synonyms |
BDCA-2; BDCA2; CLECSF11; CLECSF7; DLEC; HECL; CLEC4C; CD303; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
